Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases
Roger von Moos(Kantonsspital Graubünden), Yi Qian(Amgen (United States)), Charles S. Cleeland(The University of Texas MD Anderson Cancer Center), Danail Damyanov(National Specialized Hospital for Active Treatment of Hematologic Diseases), Arun Balakumaran(Allogene Therapeutics (United States)), Janet E. Brown(Cancer Research UK), Donald L. Patrick(University of Washington), Gavin Marx, Blair Egerdie(Urology Associates), Lesley Fallowfield(Brighton and Sussex Medical School), Ying Zhou(Children's Hospital of Fudan University), Jean-Jacques Body(National Cancer Centre Japan), Alison Stopeck(National Cancer Centre Japan), Ada Braun(Amgen (United States)), Felipe Salvador Palazzo
Cited by 79
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k